On 17 October 2019, orphan designation EU/3/19/2212 was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for leriglitazone (also known as MIN-102) for the treatment of Friedreich’s ataxia.
|Disease / condition||
Treatment of Friedreich’s ataxia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: